In addition to evaluating a post-symptomatic treatment on Sacs mice with an identified drug, Dr. Maltecca is also conducting a pre-symptomatic treatment to evaluate if such a drug can stop the neurodegeneration associated with ARSACS. Such results will be available at the end of this summer. Her work is also aimed at understanding how the drug could offer neuroprotection in ARSACS.
Dr. Maltecca expands her research
